Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China.
Shaoyan Lin(Nanjing Agricultural University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiayu Wang(Nanjing University of Chinese Medicine), Peng Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiao Li(Guangzhou University of Chinese Medicine), Qing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Shanshan Chen(Chongqing University of Posts and Telecommunications), Yiqun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Luo(Chongqing University of Posts and Telecommunications), Yimeng Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Zijing Wang(Qingdao University), Pin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Fan(Hebei North University), Xiuwen Guan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ruigang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 3
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k